

# **2019 Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025**

<https://marketpublishers.com/r/25F8C284502EN.html>

Date: April 2019

Pages: 118

Price: US\$ 1,799.00 (Single User License)

ID: 25F8C284502EN

## **Abstracts**

The global clinical trial report- "2019 Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials Study" provides complete list of trials completed, ongoing and planned for Neurofibromatoses Type I (Von Recklinghausen's Disease). It presents in-depth analysis of Neurofibromatoses Type I (Von Recklinghausen's Disease) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Neurofibromatoses Type I (Von Recklinghausen's Disease).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Neurofibromatoses Type I (Von Recklinghausen's Disease) clinical trials by-

Current Trial Status

Type of the trial

Sponsor Type

Enrollment Trends

Region

Countries

Trial Phase

The report also identifies the potential drug candidates under development for treatment of Neurofibromatosis Type I (Von Recklinghausen's Disease)

The research work is prepared through extensive and continuous research on Neurofibromatosis Type I (Von Recklinghausen's Disease) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

All major trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Neurofibromatosis Type I (Von Recklinghausen's Disease) patients are identified

The report includes panorama of Neurofibromatosis Type I (Von Recklinghausen's Disease) clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Neurofibromatosis Type I (Von Recklinghausen's Disease) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

## Contents

### 1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

### 2. EXECUTIVE SUMMARY

2.1 Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials Overview, 2019

2.2 Premium Insights into Clinical Trials

2.2.1 Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Region

2.2.2 Average Enrollment of Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials

2.2.3 Companies participating in Trials

2.2.4 Drugs under Study for Neurofibromatoses Type I (Von Recklinghausen's Disease) Treatment, 2019

### 3. REGION WISE NEUROFIBROMATOSSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) CLINICAL TRIALS

3.1 Asia Pacific Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Country

3.2 Europe Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Country

3.3 North America Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Country

3.4 Middle East and Africa Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Country

3.5 South and Central America Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Country

### 4. NEUROFIBROMATOSSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) CLINICAL TRIAL TRENDS

4.1 Start Year wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials

4.2 Phase wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials

4.3 Trial Status wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials

4.4 Trial Type wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials

## **5. NEUROFIBROMATOSSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) AVERAGE ENROLLMENT TRENDS**

5.1 Average Enrollment in Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials by Year

5.2 Average Enrollment in Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials by Phase

5.3 Average Enrollment in Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials by Status

5.4 Average Enrollment in Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials by Type of Trial

## **6. COMPANIES PARTICIPATING IN NEUROFIBROMATOSSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) CLINICAL TRIALS**

6.1 Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials by Sponsor Type

6.2 Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Sponsor Type

6.3 Subjects Recruited by Leading Sponsors

## **7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS**

7.1 Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials- Phase

7.2 Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials- Phase

7.3 Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials- Phase

7.4 Neurofibromatoses Type I (Von Recklinghausen's Disease) Trials- Phase

## **8. APPENDIX**

8.1 Report Guidance

8.2 Research Methodology

8.3 Abbreviations

8.4 Definitions

8.5 Sources

8.6 Publisher Expertise

## List Of Figures

### LIST OF FIGURES

- Figure 1: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Region, 2019
- Figure 2: Country wise Clinical Trials, 2019
- Figure 3: Country wise Average Enrolment, 2019
- Figure 4: Asia Pacific – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment
- Figure 5: Europe – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment
- Figure 6: Middle East Africa – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment
- Figure 7: North America – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment
- Figure 8: South and Central America – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment
- Figure 9: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Phase
- Figure 10: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Trial Status
- Figure 11: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Type
- Figure 12: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Sponsor Type
- Figure 13: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials by Leading Sponsors
- Figure 14: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Phase
- Figure 15: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Trial Status
- Figure 16: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Type
- Figure 17: Neurofibromatoses Type I (Von Recklinghausen's Disease)- Average Enrolment by Type of Sponsors
- Figure 18: Neurofibromatoses Type I (Von Recklinghausen's Disease)- Enrolment by Leading Sponsors
- Figure 19: VPAResearch- Research Methodology





## List Of Tables

### LIST OF TABLES

Table 1: Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials Snapshot- 2019

Table 2: Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment

Table 5: Europe – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment

Table 7: North America – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Phase

Table 15: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Trial Status

Table 16: Neurofibromatoses Type I (Von Recklinghausen's Disease) Average Enrollment by Type

Table 17: Neurofibromatoses Type I (Von Recklinghausen's Disease)- Average Enrolment by Type of Sponsors

Table 18: Neurofibromatoses Type I (Von Recklinghausen's Disease)- Enrolment by Leading Sponsors

## I would like to order

Product name: 2019 Neurofibromatoses Type I (Von Recklinghausen's Disease) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

Product link: <https://marketpublishers.com/r/25F8C284502EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/25F8C284502EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

